Proficiency Testing for CF Newborn Screening  by Earley, M.C. et al.
2. Screening/Diagnosis S11
38* Implementation of the UK Newborn Screening Programme
K.W. Southern1, D. Sinclair2, B. Judge3, R.J. Pollitt4, I.J. Doull5, D.M. Bradley6,
J.F. Price7. 1Child Health, University of Liverpool, Liverpool, United Kingdom;
2Biochemistry, Queen Alexandra Hospital, Portsmouth, United Kingdom; 3National
NBS Programme Centre, Great Ormond Street Hospital, London, United Kingdom;
4Clinical Chemistry, Shefﬁeld Children’s Hospital, Shefﬁeld, United Kingdom;
5Regional CF Centre, University Hospital of Wales, Cardiff, United Kingdom;
6Medical Biochemistry, University Hospital of Wales, Cardiff, United Kingdom;
7Regional CF Centre, Kings College Hospital, London, United Kingdom
CF newborn screening (NBS) in the UK was developed to complement the national
programme with IRT measurement on the day 5 blood spot sample. A cut-off
of 99.5% would determine which samples were sent for DNA analysis for the 4
commonest UK mutations (one mutation would prompt analysis with a 29 mutation
panel). A second IRT (IRT-2) would be measured in the third week of life in infants
with one mutation (assessment including sweat test only if IRT-2 elevated). Second
IRT measurements were also undertaken on infants with a very high initial IRT
(>99.9th centile) and no mutation identiﬁed.
From April 2007 to March 2008, 589,931 infants were screened and 3253 referred
for DNA analysis (0.55%). 149 babies had 2 CF mutations (in 40 the second
mutation was recognised from the extended 29 mutation panel). A further 75 infants
were referred for assessment following a raised IRT-2, 40 of whom had one mutation
detected (complete data not yet available). 140 (0.023%) putative carriers were
recognized (one mutation and IRT-2 not raised).
The UK programme has achieved its aim of limiting the number of families referred
for assessment (sweat testing). This does not appear to be at the expense of case
recognition. A positive aspect has been the low proportion of putative carriers; the
reasons for this are less clear but may relate to IRT cut-offs and the limited panel
of four mutations in the ﬁrst DNA screen.
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Objective: To serve the NBS community in the US and abroad, the Newborn
Screening Quality Assurance Program developed 3 proﬁciency testing (PT) pro-
grams: immunoreactive trypsinogen (IRT), IRT/F508del, and multiple mutation
detection.
Methods: Dried blood spot (DBS) materials for IRT testing were created using a
whole blood matrix and IRT (2002-present). DBS materials for DNA testing were
created using a whole blood matrix, IRT, and transformed lymphoblast cell lines
containing 1 or 2 copies of the F508del mutation (2004–2008) or prepared from
adult or adolescent CF patients (2007–2008). PT specimens were sent quarterly.
Data collected included method used, clinical assessment, IRT concentration and/or
genotype detected. Data was graded based on the clinical assessment.
Results: IRT and F508del data results are based on results from 2002–2007. The
false negative rate for US and Canadian laboratories was 0.67% (n = 1670 results)
and 0.67% for foreign laboratories. 2% of DNA results were incorrect for US and
Canadian laboratories (n = 316 results) with a 1% sample failure rate and 7% of
results were incorrect for foreign laboratories (n = 3414 results) with a 10% sample
failure rate. For the multiple mutation detection program, 8% of results from US
and Canadian laboratories were not evaluated because of sample failure or because
mutations could not be tested. Only 2% of results were incorrect (n = 609 results).
In contrast, 38% of results from foreign laboratories were not evaluated because of
sample failure or because mutations could not be tested. Of the results evaluated,
6% were incorrect (n = 295 results).
Conclusions: PT programs are an important component of monitoring laboratory
performance. Overall, this data has shown that NBS laboratories worldwide are able
to provide consistent, reliable results for CF NSB.
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Between 1973 and 2008 426 patients (218F, 208M) have been diagnosed by the
neonatal screening program in Veneto, a north-eastern region of Italy of approx 5
million inhabitants. We performed a survival analysis (Kaplan-Meier) and studied
the inﬂuence on survival of relevant risk factors in pts diagnosed by symptoms.
Similarly to the rest of Italian CF population, 80% of the CFTR mutations were
accounted for by 8 mutation (F508del, R1162X, 2183AA→G, N1303K, G542X,
711+5G→A, 1717−1G→A, R553X). The n of deaths was 31 (14M, 17F). Survival
probability exceeded 80% at 25 years. There was no signiﬁcant difference in survival
probability in M vs F, PI vs PS patients, diabetics vs non diabetics (deﬁned
by insulin treatment) although F tended to need insulin Tx earlier (log-rank test
p = 0.06)and tended to be listed earlier for lung transplant (p = 0.07). We conclude
that pts. diagnosed by neonatal screening have elevated survival probability through
adulthood and survival is not affected by established risk factors in pts diagnosed
by symptoms.
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Introduction: The aim of this project was to determine a consensus with respect
to the early management of infants recognised to have CF following NBS.
Methods: A modiﬁed Delphi methodology was used. A core group reviewed the
literature, graded the available evidence and produced 41 statements. All members
of the ECFS were invited to participate in the consensus via e mail. Additional
invitations were made to increase multidisciplinary input. The specialist was asked
to rate their agreement for each statement. In the case of disagreement, comments
were requested. The level of agreement constituting consensus was determined
a priori to be 80%. After round 1, statements not achieving consensus were
modiﬁed by the core group, taking into account comments. In round two, the
initial statements, degree of agreement, summary of comments, and a second set
of proposed statements were circulated to all respondents. 4 additional statements
were included based on participants’ suggestions. The process is ongoing in order
to achieve consensus for all statements.
Results: After two rounds of the Delphi process, 43 statements have >80%
agreement and will go forward to the consensus document. In two statements
consensus was not achieved. One statement considered whether and what blood
tests were needed for a baseline assessment and the second was a new statement
following suggestions from round 1, which discussed need for the family to contact
the CF team at any time. The core group is currently reviewing these statements.
Conclusion: This methodology has enabled development of a consensus document
that will provide a valuable tool for CF teams both with established programmes
and those in the process of implementing NBS.
